Akeso’s Cadonilimab Approved for 1st-Line Cervical Cancer Treatment
Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company’s first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line...